Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2015

01-01-2015 | Review

Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells

Authors: Chenxiao Yu, Jiao Xue, Wei Zhu, Yang Jiao, Shuyu Zhang, Jianping Cao

Published in: Tumor Biology | Issue 1/2015

Login to get access

Abstract

Unlike normal differentiated cells, cancer cells primarily rely on glycolysis to generate energy needed for cellular processes even in normoxia conditions. This phenomenon is called aerobic glycolysis or “the Warburg effect.” Aerobic glycolysis is inefficient to generate ATP, but the advantages it confers to cancer cells remain to be fully explained. Several oncogenic signaling pathways, interplaying with enzymes and kinases involved in glucose metabolism, participate in the switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis. Non-coding RNAs (ncRNAs) are a family of functional RNA molecules that are not further translated into proteins, which exert regulatatory roles in gene transcription and translation. ncRNAs, especially miRNAs and long non-coding RNAs (lncRNAs), may also have great effect on glucose metabolism by targeting not only glycolysis enzymes directly but also oncogenic signaling pathways indirectly. A better understanding of the Warburg effect and the regulatory role of ncRNAs in cancer glucose metabolism may contribute to the treatment of cancers.
Literature
1.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed
2.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.PubMedPubMedCentral
3.
Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425–34.PubMed
4.
Szymanski M et al. Noncoding RNA transcripts. J Appl Genet. 2003;44(1):1–20.PubMed
5.
Hüttenhofer A, Schattner P, Polacek N. Non-coding RNAs: hope or hype? Trends Genet. 2005;21(5):289–97.PubMed
6.
Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376–85.PubMed
7.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMed
8.
9.
Han J et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006;125(5):887–901.PubMed
10.
Denli AM et al. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231–5.PubMed
11.
Yi R et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011–6.PubMedPubMedCentral
12.
13.
Gregory RI et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631–40.PubMed
14.
15.
Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115(2):209–16.PubMed
16.
17.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.PubMed
18.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.PubMed
19.
Mercer TR et al. Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci. 2008;105(2):716–21.PubMedPubMedCentral
20.
Babak T, Blencowe BJ, Hughes TR. Considerations in the identification of functional RNA structural elements in genomic alignments. BMC Bioinforma. 2007;8(1):33.
21.
Seto AG, Kingston RE, Lau NC. The coming of age for PIWI proteins. Mol Cell. 2007;26(5):603–9.PubMed
22.
Gunawardane LS et al. A slicer-mediated mechanism for repeat-associated siRNA 5′end formation in Drosophila. Science. 2007;315(5818):1587–90.PubMed
23.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.PubMed
24.
Lehninger N, Cox MN. Principles of biochemistry. New York: WH Freeman & Co.; 2008.
25.
DeBerardinis RJ et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci. 2007;104(49):19345–50.PubMedPubMedCentral
26.
DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148(6):1132–44.PubMedPubMedCentral
27.
28.
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705–13.PubMed
29.
Quagliaro L et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells the role of protein kinase C and NAD (P) H-oxidase activation. Diabetes. 2003;52(11):2795–804.PubMed
30.
Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45.PubMed
31.
Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577–90.PubMed
32.
Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8(11):851–64.PubMed
33.
34.
Kato M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci. 2007;104(9):3432–7.PubMedPubMedCentral
35.
Yang H et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–33.PubMed
36.
Uesugi A et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71(17):5765–78.PubMed
37.
Wang J et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog. 2013;9(10):e1003697.PubMedPubMedCentral
38.
Meng F et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.PubMedPubMedCentral
39.
Aguda BD et al. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci. 2008;105(50):19678–83.PubMedPubMedCentral
40.
41.
Liang Z et al. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28(12):3091–100.PubMedPubMedCentral
42.
Kefas B et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68(10):3566–72.PubMed
43.
Tsukamoto Y et al. MicroRNA-375 is down regulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3ζ. Cancer Res. 2010;70(6):2339–49.PubMed
44.
Matoba S et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–3.PubMed
45.
Samuels-Lev Y et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8(4):781–94.PubMed
46.
Li Q et al. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res. 2007;67(1):66–74.PubMed
47.
Shikama N et al. A novel cofactor for p300 that regulates the p53 response. Mol Cell. 1999;4(3):365–76.PubMed
48.
Kumar M et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2011;30(7):843–53.PubMed
49.
Ji P et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41.PubMed
50.
Zhang X et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology. 2010;151(3):939–47.PubMed
51.
Weger S, Hammer E, Heilbronn R. Topors, a p53 and topoisomerase I binding protein, interacts with the adeno-associated virus (AAV-2) Rep78/68 proteins and enhances AAV-2 gene expression. J Gen Virol. 2002;83(3):511–6.PubMed
52.
53.
Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci. 2008;105(36):13421–6.PubMedPubMedCentral
54.
Zhong H et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60(6):1541–5.PubMed
55.
Iyer NV et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12(2):149–62.PubMedPubMedCentral
56.
Ryan HE, Lo J, Johnson RS. HIF‐1α is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17(11):3005–15.PubMedPubMedCentral
57.
Taguchi A et al. Identification of hypoxia-inducible factor-1α as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008;68(14):5540–5.PubMed
58.
Burant CF, Bell GI. Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally monomeric proteins. Biochemistry. 1992;31(42):10414–20.PubMed
59.
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654–62.PubMed
60.
Joost H-G et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab. 2002;282(4):E974–6.PubMed
61.
Thorens H-G, Bernard J. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol. 2001;18(4):247–56.PubMed
62.
Fabani MM, Gait MJ. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates. RNA. 2008;14(2):336–46.PubMedPubMedCentral
63.
Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res. 2010;86(3):410–20.PubMed
64.
Yamasaki T et al. Tumor‐suppressive microRNA‐1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci. 2013;104(11):1411–9.PubMed
65.
Fang R et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 2012;287(27):23227–35.PubMedPubMedCentral
66.
Gregersen LH et al. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12(1):232.PubMed
67.
Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43(7):969–80.PubMed
68.
Liu AM et al. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS One. 2014;9(1):e86872.PubMedPubMedCentral
69.
Burchard J, et al. MicroRNA‐122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6(1).
70.
Bruning U et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1α activity during prolonged hypoxia. Mol Cell Biol. 2011;31(19):4087–96.PubMedPubMedCentral
71.
Yang F, et al. Reciprocal regulation of HIF-1α and LincRNA-p21 modulates the Warburg effect. Mol Cell. 2013.
72.
Aschrafi A et al. MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J Neurosci. 2008;28(47):12581–90.PubMedPubMedCentral
73.
Bhaskar PT, Hay N. The two TORCs and AKT. Dev Cell. 2007;12(4):487–502.PubMed
74.
Robey RB, Hay N. Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis. In: Seminars in cancer biology. 2009. Elsevier.
75.
Gottlob K et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15(11):1406–18.PubMedPubMedCentral
76.
Nogueira V et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 2008;14(6):458–70.PubMedPubMedCentral
77.
Kohn AD et al. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271(49):31372–8.PubMed
78.
Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267–77.PubMed
79.
Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005;65(22):10545–54.PubMed
80.
Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15(3):521–9.PubMed
81.
Robey RA, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25(34):4683–96.PubMed
82.
Deprez J et al. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997;272(28):17269–75.PubMed
83.
Skeen JE et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 2006;10(4):269–80.PubMed
84.
Gingras A-C et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev. 1998;12(4):502–13.PubMedPubMedCentral
85.
Hahn-Windgassen A et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280(37):32081–9.PubMed
86.
Majumder PK et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10(6):594–601.PubMed
87.
Kato M et al. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–9.PubMedPubMedCentral
88.
Guo C et al. The noncoding RNA, miR‐126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3‐kinase signaling and is frequently lost in colon cancers. Genes Chromosom Cancer. 2008;47(11):939–46.PubMedPubMedCentral
89.
Wang F, et al. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919–27.
90.
Wu W et al. Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One. 2013;8(9):e73920.PubMedPubMedCentral
91.
Poliseno L et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465(7301):1033–8.PubMedPubMedCentral
92.
Li D et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol. 2013;182(1):64–70.PubMed
93.
Kahn BB et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15–25.PubMed
94.
Hardie DG. AMP-activated protein kinase—an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895–908.PubMedPubMedCentral
95.
Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137–63.PubMed
96.
Shaw RJ et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A. 2004;101(10):3329–35.PubMedPubMedCentral
97.
Sakamoto K et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 2005;24(10):1810–20.PubMedPubMedCentral
98.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32.PubMed
99.
Godlewski J et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620–32.PubMedPubMedCentral
100.
Chen H et al. Micro-RNA-195 and-451 regulate the LKB1/AMPK signaling axis by targeting MO25. PLoS One. 2012;7(7):e41574.PubMedPubMedCentral
101.
Nandi S, Mishra P. miR-133a alleviates cardiac autophagy by targeting AMPK in Ins2+/−diabetic mice (868.3). FASEB J. 2014;28(1 Supplement):868.3.
102.
Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol. 2007;17(6):286–91.PubMed
103.
Kondoh H et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005;65(1):177–85.PubMed
104.
Bensaad K et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–20.PubMed
105.
Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68(19):8164–72.PubMed
106.
Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun. 2005;331(3):778–85.PubMed
107.
Moumen A et al. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell. 2005;123(6):1065–78.PubMed
108.
109.
Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53. Cell Cycle. 2009;8(5):712–5.PubMed
110.
Tripathi V et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9(3):e1003368.PubMedPubMedCentral
111.
Zhang X et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 2010;70(6):2350–8.PubMedPubMedCentral
112.
Mahmoudi S et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 2009;33(4):462–71.PubMed
113.
Kim H et al. The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells. Oncogene. 2001;20(37):5118–23.PubMed
114.
Zhang A, Xu M, Mo Y-Y. Role of the lncRNA−p53 regulatory network in cancer. J Mol Cell Biol. 2014. p. mju013.
115.
Huarte M et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.PubMedPubMedCentral
116.
117.
Hung T et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43(7):621–9.PubMedPubMedCentral
118.
119.
Dugimont T, et al. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene. 1998;16(18).
120.
Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343–54.PubMed
121.
Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402.PubMed
122.
Ivan M et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–8.PubMed
123.
Jaakkola P et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72.PubMed
124.
Maxwell PH et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.PubMed
125.
Fukuda R et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277(41):38205–11.PubMed
126.
Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63(9):2330–4.PubMed
127.
Kim J-W et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–85.PubMed
128.
Song T et al. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12(5):1307–11.PubMed
129.
Rane S et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009;104(7):879–86.PubMedPubMedCentral
130.
Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta (BBA) Bioenerg. 2011;1807(6):620–5.
131.
132.
Bian Z et al. Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions. Cell Res. 2010;20(9):1076–8.PubMed
133.
Lakomy R et al. MiR‐195, miR‐196b, miR‐181c, miR‐21 expression levels and O‐6‐methylguanine‐DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011;102(12):2186–90.PubMed
134.
Scapoli L et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 2009;23(4):1229–34.
135.
Huang X et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35(6):856–67.PubMedPubMedCentral
136.
Chan SY et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10(4):273–84.PubMedPubMedCentral
137.
Zhang X et al. MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell. 2014;158(3):607–19.PubMedPubMedCentral
138.
Michelakis E, Webster L, Mackey J. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989–94.PubMedPubMedCentral
139.
Keller K, Strube M, Mueckler M. Functional expression of the human HepG2 and rat adipocyte glucose transporters in Xenopus oocytes. Comparison of kinetic parameters. J Biol Chem. 1989;264(32):18884–9.PubMed
140.
Horie T et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun. 2009;389(2):315–20.PubMed
141.
Chen Y-H et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013;62(7):2278–86.PubMedPubMedCentral
142.
Chow T-fF et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol. 2010;183(2):743–51.PubMed
143.
144.
Peschiaroli A et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMed
145.
Park YY et al. Tat‐activating regulatory DNA‐binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013;58(1):182–91.PubMedPubMedCentral
146.
Kefas B et al. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010;12(11):1102–12.PubMedPubMedCentral
147.
148.
Coulouarn C et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–36.PubMedPubMedCentral
149.
150.
Ding G et al. MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1α. Mol Cell Biochem. 2013;384(1–2):173–80.PubMed
151.
Papandreou I et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–97.PubMed
152.
Kim H-R et al. p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun. 2013;437(2):225–31.PubMed
153.
Kaller M et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics. 2011;10(8):M111. 010462.PubMedPubMedCentral
154.
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–82.PubMed
Metadata
Title
Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells
Authors
Chenxiao Yu
Jiao Xue
Wei Zhu
Yang Jiao
Shuyu Zhang
Jianping Cao
Publication date
01-01-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2875-z

Other articles of this Issue 1/2015

Tumor Biology 1/2015 Go to the issue

Research Article

Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer

Research Article

A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer

Review

Incorporation of biomarkers in phase II studies of recurrent glioblastoma

Review

SMAD4 and its role in pancreatic cancer

Research Article

miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma

Research Article

Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits